HUP0302882A2 - Javított specificitás betegségek kezelésében - Google Patents

Javított specificitás betegségek kezelésében

Info

Publication number
HUP0302882A2
HUP0302882A2 HU0302882A HUP0302882A HUP0302882A2 HU P0302882 A2 HUP0302882 A2 HU P0302882A2 HU 0302882 A HU0302882 A HU 0302882A HU P0302882 A HUP0302882 A HU P0302882A HU P0302882 A2 HUP0302882 A2 HU P0302882A2
Authority
HU
Hungary
Prior art keywords
blocking group
active
active ingredient
selectivity
reduction
Prior art date
Application number
HU0302882A
Other languages
English (en)
Inventor
Zhi Hong
Johnson Lau
Chin-Chung Lin
Original Assignee
Icn Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals, Inc. filed Critical Icn Pharmaceuticals, Inc.
Publication of HUP0302882A2 publication Critical patent/HUP0302882A2/hu
Publication of HUP0302882A3 publication Critical patent/HUP0302882A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya eljárás gyógyszerhatóanyag szelektivitásának anövelésére egy farmakológiai hatás szempontjából. A találmány szerintegy hatóanyagot úgy módosítanak, hogy a hatóanyaghoz egy blokkolócsoportot kovalens módon kapcsolnak, a blokkoló csoportban levőnitrogénatom útján. A módosított hatóanyagban levő blokkoló csoportmeggátolja a hatóanyag metabolikus átalakulását és kötődését a nemcélsejtekben, és a blokkoló csoportot enzimatikus úton a célsejtbentávolítják el. Az ismertetett vegyületek és eljárások különösenfigyelemre méltó előnyei közé tartoznak a citotoxicitás csökkentéseesetleg citotoxikus metabolitokhoz vezető metabolikus átalakulásgátlásával; a hatóanyagok adagolási mennyiségeinek csökkentése a nemcélsejtekben végbemenő kötődés csökkentésével; valamint a hatóanyagszelektivitásának a növelése. Ó
HU0302882A 2000-08-22 2000-12-07 Improved specificity in treatment of diseases HUP0302882A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22687000P 2000-08-22 2000-08-22
US22694800P 2000-08-22 2000-08-22
US22687100P 2000-08-22 2000-08-22
PCT/US2000/033454 WO2002016382A1 (en) 2000-08-22 2000-12-07 Improved specificity in treatment of diseases

Publications (2)

Publication Number Publication Date
HUP0302882A2 true HUP0302882A2 (hu) 2003-12-29
HUP0302882A3 HUP0302882A3 (en) 2005-06-28

Family

ID=27397667

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302882A HUP0302882A3 (en) 2000-08-22 2000-12-07 Improved specificity in treatment of diseases

Country Status (15)

Country Link
EP (1) EP1351966A1 (hu)
JP (1) JP2004518618A (hu)
KR (1) KR20030040415A (hu)
CN (1) CN1460109A (hu)
AU (1) AU2001220806A1 (hu)
BR (1) BR0017318A (hu)
CA (1) CA2416748A1 (hu)
CZ (1) CZ2003460A3 (hu)
HU (1) HUP0302882A3 (hu)
IL (1) IL154168A0 (hu)
MX (1) MXPA03001528A (hu)
NO (1) NO20030762L (hu)
PL (1) PL365879A1 (hu)
TW (1) TW200414903A (hu)
WO (1) WO2002016382A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN100448879C (zh) * 2004-07-22 2009-01-07 北京化工大学 一种无定型头孢呋辛酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
USRE29835E (en) * 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3991078A (en) * 1971-06-01 1976-11-09 Icn Pharmaceuticals, Inc. N-substituted 1,2,4-triazoles
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US4093624A (en) * 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
JPS6426593A (en) * 1987-07-21 1989-01-27 Asahi Glass Co Ltd Nucleoside derivative
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates

Also Published As

Publication number Publication date
KR20030040415A (ko) 2003-05-22
EP1351966A1 (en) 2003-10-15
NO20030762D0 (no) 2003-02-18
CZ2003460A3 (cs) 2003-10-15
AU2001220806A1 (en) 2002-03-04
TW200414903A (en) 2004-08-16
HUP0302882A3 (en) 2005-06-28
CN1460109A (zh) 2003-12-03
IL154168A0 (en) 2003-07-31
CA2416748A1 (en) 2002-02-28
MXPA03001528A (es) 2004-04-02
PL365879A1 (en) 2005-01-10
BR0017318A (pt) 2004-06-15
WO2002016382A1 (en) 2002-02-28
JP2004518618A (ja) 2004-06-24
NO20030762L (no) 2003-04-22

Similar Documents

Publication Publication Date Title
NZ514574A (en) Novel method of treatment
NO20013855L (no) Fast tilstandsform av celecoxib med ökt biotilgjengelighet
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
TW200503775A (en) Pharmaceutical composition and method for treating
ATE387912T1 (de) Transepikutane darreichungsform zur behandlung des restless leg syndroms
IL122401A0 (en) Anti-inflammatory compositions
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
EA200000355A2 (ru) Промышленные изделия
CN103635191A (zh) 小分子rna酶抑制剂和使用方法
MY196807A (en) Chromane, isochromane and dihydroisobenzofuran derivatives as mglur2-negative allosteric modulators, compositions, and their use
HK1059738A1 (en) Methods and pharmaceutical compositions for healing wounds
MXPA05012675A (es) Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.
UA89795C2 (ru) Фармацевтическая композиция, которая содержит эстер темозоломида
WO2006113718A3 (en) Compositions for the treatment of neoplasms
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
HUP0302882A2 (hu) Javított specificitás betegségek kezelésében
DK1549329T3 (da) Ekstrakt med antitumoraktivitet og anti-giftaktivitet
ATE374615T1 (de) Verwendung von sumsoo-extrakt in pharmazeutischen verbindungen zur prävention und behandlung erektiler impotenz
GB0111078D0 (en) Organic compounds